Applications
Biocon launches Ustekinumab biosimilar Yesintek in US market
MUMBAI: Biocon Biologics Ltd has announced the US launch of Yesintek (ustekinumab-kfce), one of the first biosimilars to Janssen’s Stelara® to enter the American market.
The biosimilar, approved by the US Food and Drug Administration in December 2024, is indicated for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. Yesintek will be available in all formulations currently offered by the reference product.
Biocon Biologics chief executive officer & managing director Shreehas Tambe called the launch “a significant step in our commitment to improving the lives of patients with inflammatory conditions” and noted it represents the company’s first US product launch since becoming a fully integrated global biosimilars organisation.
The monoclonal antibody disrupts IL-12 and IL-23 mediated signalling associated with immune-mediated diseases. Clinical studies demonstrated Yesintek has similar pharmacokinetic, safety, efficacy and immunogenicity profiles compared with Stelara®.
Crohn’s & Colitis Foundation chief education, support and advocacy officer Laura Wingate described the launch as “a meaningful advancement for eligible chronic disease patients, who now have more treatment options available.”
Biocon confirmed Yesintek will have commercial payer coverage at launch alongside a patient assistance programme that includes benefits verification and copay support, with eligible patients potentially paying as little as $0.
Josh Salsi, head of North America at Biocon Biologics Inc, emphasised that healthcare providers switching to Yesintek can expect “a seamless treatment experience covering the same indications and dosing options.”
Applications
With 57 per cent single new users, Ashley Madison rebrands as discreet dating platform
Platform says majority of new members now identify as single
INDIA: Ashley Madison is shedding the “married-dating” label that defined it for two decades, repositioning itself as a platform for discreet dating in what it calls the post-social media age.
The rebrand, unveiled in India on 27 February, 2026, marks a structural shift in business model and identity. Once synonymous with married dating, the company now describes itself as the “premier destination for discreet dating” under a new tagline: Where Desire Meets Discretion.
The pivot is data-driven. Internal figures show that 57 per cent of global sign-ups between 1 January and 31 December, 2025 identified as single: a notable departure from the platform’s married core. The company argues that its community has already evolved beyond its original positioning.
“In an age where our lives have been constantly put on public display, privacy has become the new luxury,” said Ashley Madison chief strategy officer Paul Keable. He framed the platform’s offering as “ethical discretion” for singles, separated, divorced and non-monogamous users seeking private connections.
The shift also taps into wider digital fatigue. A global survey conducted by YouGov for Ashley Madison, covering 13,071 adults across Australia, Brazil, Canada, Germany, India, Italy, Mexico, Spain, Switzerland, the UK and the US, found mounting discomfort with hyper-public online lives.
Among dating app users, 30 per cent cited constant swiping and messaging as a source of fatigue, while 24 per cent pointed to pressure to curate public-facing profiles and early personal disclosure. Some 27 per cent said fears of screenshots or information being shared contributed to exhaustion; an equal share cited unwanted attention.
The retreat from oversharing appears broader. According to the survey, 46 per cent of adults actively try to keep most aspects of their life private online. Only 8 per cent feel comfortable sharing most aspects publicly, while 35 per cent say they are becoming more selective about what they disclose.
Ashley Madison is betting that this cultural recalibration towards controlled visibility can be monetised. By doubling down on privacy infrastructure and reframing itself around discretion rather than infidelity, the company is attempting to convert reputational baggage into a premium proposition.
